Loading
A phase 3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company in non-small-cell lung cancer and small-cell lung cancer, now recruiting.
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is a phase 3 interventional study registered as NCT05989542 by Beijing Pearl Biotechnology Limited Liability Company, with 136 participants planned, started 2023-10-16. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, Small-molecule kinase inhibitors.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.